Quantcast

Industry news that matters to you.  Learn more

Archives for October 2012

Scientists at Scripps Research Develop Novel Technology to Identify Biomarkers for Ulcerative Colitis

Scientists from the Florida campus of The Scripps Research Institute have developed a novel technology that can identify, in animal models, potential biomarkers of ulcerative colitis, a type of inflammatory bowel disease that affects the lining of the colon.

Data Published Identify the Folate Receptor as a Potential Biomarker for Targeted Therapies in a Majority of Lung Cancers

Endocyte, Inc. (NASDAQ Global Market: ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, recently announced the publication of data showing that 72 percent of adenocarcinomas and 51 percent of squamous cell carcinomas of the lung were positive for the folate receptor (FR). Currently validated targeted therapies are effective in only a small minority of lung cancers so the FR may be an important molecular target for future lung cancer therapies. The data are published online in the journal Archives of Pathology & Laboratory Medicine.

Critical Diagnostics Accelerates European Rollout of Presage ST2 Assay

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, today announced that it has signed agreements with four new European distributors in Germany, Spain, France and Turkey.

NextBio Teams With Emory University for Cancer Biomarker Discovery

NextBio recently announced a partnership with Emory University and its Winship Cancer Institute using genomic data to identify unique biomarkers and treatments for patients with multiple myeloma. The centerpiece of the partnership is a translational research study that will use NextBio Clinical to interpret molecular data from patients with multiple myeloma, with the ultimate goal of making new discoveries that will improve the care of patients with refractory and relapsed forms of myeloma. These forms of myeloma, a plasma cell cancer that constitutes about 1% of all cancers in the United States, have been particularly challenging to treat.

BioFortis Inc., Introduces Next Generation Biobanking Software Platform for Biomarker-Based Clinical Research

BioFortis Inc., a leading software company in the clinical and translational research space, recently introduced its Next Generation Biobanking software platform for biomarker-based clinical research. It will help pharmaceutical, government and academic research centers involved in biomarker-based clinical and translational studies to safely and effectively conduct externalized, science-driven collaborative studies.

As biomarker-based clinical research has become more commonplace, organizations have looked to biobanks to help drive these studies. However, this approach poses significant challenges to conventional biobanks and their software. The Next Generation Biobanking software platform is designed to overcome these challenges by harmonizing biospecimen data with clinical and molecular data in a collaborative environment that emphasizes scientific insights, while ensuring security and compliance.

At the core of the Next Generation Biobanking software solution is the Labmatrix® platform. Labmatrix goes beyond the sample-centric workflows of conventional biobanking software by integrating patient, clinical, specimen, genetic and molecular assay data, to deliver holistic views of studies. Multi-level user access control ensures that all collaborators can work effectively while maintaining relevant privacy and regulatory compliance objectives.

Driving scientific insights is one of the key benefits of Next Generation Biobanking software. Mining the wealth of data across studies, searching for the patterns within, and discovering knowledge requires tools that augment the user’s own expertise. To meet that need, the Next Generation Biobanking software platform provides Qiagram®, the award-winning visual ad hoc query tool. Qiagram puts powerful query and knowledge discovery tools in the hands of the individual researcher. Users “draw” their questions, interactively creating sophisticated queries, without the need to program or struggle with complicated query builders. Answers are presented in configurable visualizations and dashboard widgets that can be shared to generate cross-study, cross-site and cross-group knowledge.

“Based on experiences with many pharmaceutical companies and academic centers, we believe that our Next Generation Biobanking software bridges the gap between conventional biobanking software and the needs of biomarker-based clinical research,” commented BioFortis CEO, Jian Wang, PhD, “We consider it critical to empower researchers to perform these kinds of studies and deliver safer and effective clinical outcomes.”

Source: PR Newswire